Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
04:38pm, Tuesday, 01'st Nov 2022 Benzinga
Gainers
Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.
Abiomed, Inc. (NASDAQ: ABMD) shares jumped 50.4%
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
03:36pm, Tuesday, 01'st Nov 2022 Benzinga
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Varonis Systems, Inc. (NASDAQ: VRNS) shares tum
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
12:15pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
11:00am, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021—
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
10:07am, Tuesday, 01'st Nov 2022
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - Chief
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
09:48am, Tuesday, 01'st Nov 2022
BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
11:00am, Monday, 24'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts, including one Distinguishe
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts, including one Distinguished
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
BioCryst to Report Third Quarter 2022 Financial Results on November 1
11:00am, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results T
BioCryst to Report Third Quarter 2022 Financial Results on November 1
07:00am, Tuesday, 18'th Oct 2022
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tue
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Tuesday, 04'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran
Got $3,000? Here Are 2 Stocks That Will Make You Richer
11:54am, Sunday, 02'nd Oct 2022 The Motley Fool
BioCryst Pharmaceuticals and Steris could both deliver outstanding returns for patient shareholders.
